https://www.selleckchem.com/products/hdm201.html
Background The use of Impella® to provide hemodynamic support during unprotected left main coronary artery (LMCA) percutaneous coronary intervention (PCI) has been shown to be feasible, but severe AS is a relative contraindication for its use. Balloon aortic valvuloplasty (BAV) may facilitate the use of Impella® in these patients. Objective To assess the feasibility of BAV followed by Impella®-assisted LMCA PCI in patients with severe AS as bridge to TAVR. Methods Patients with symptomatic severe AS with LMCA stenosis ≥70% requiring PCI
Like
Comment
Share
